Minerva Neurosciences

NERV · NASDAQ

$2.53+$0.21 (+9.05%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.32

NERV analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 5 analysts

Average $10.54 (+316.6% upside)

Low: $7.07
Now: $2.53
High: $14.70

Upgrades and downgrades

The latest rating actions, newest first

NERV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jefferies	Aug 14, 2026	Upgrade	Hold → Buy	$7.50 → $10.00	40%
Citizens	Apr 15, 2026	Initiates	Market Outperform	$14.00	41%
HC Wainwright & Co.	Mar 12, 2026	Maintains	Neutral	$4.00 → $7.00	50%
HC Wainwright & Co.	Nov 6, 2025	Maintains	Neutral	$5.00 → $4.00	50%

The case for and against

Updated Sep 1, 2026

Bull case

Minerva Neurosciences is well-positioned for long-term success with a promising drug in its pipeline, a well-structured development plan, and strong leadership. The potential for blockbuster sales in a large global market makes this stock an attractive investment opportunity. However, regulatory risks should be closely monitored as the drug targets unique receptors. With a solid financial foundation and experienced leadership, Minerva Neurosciences shows potential for significant growth and profitability in the future.

Bear case

Minerva Neurosciences is currently focused on the development and commercialization of proprietary product candidates to treat CNS diseases, with a primary focus on its leading product Roluperidone. However, challenges lie ahead as Minerva must execute a successful confirmatory Phase 3 trial for the treatment of negative symptoms in patients with schizophrenia. Despite promising results in previous trials, a high placebo response rate remains a key concern, and the company must continue to carefully manage this in order to achieve regulatory approval. Additionally, concerns remain around the company's financials, with negligible product sales and reliance on external funding sources, such as the recent private placement and shelf offering, to continue operations.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.